Log in

NASDAQ:NTLA - Intellia Therapeutics Stock Price, Forecast & News

$14.63
-0.53 (-3.50 %)
(As of 01/19/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.61
Now: $14.63▼
$15.38
50-Day Range
$13.87
MA: $15.79▼
$17.67
52-Week Range
$10.26
Now: $14.63▼
$19.00
Volume684,327 shs
Average Volume516,338 shs
Market Capitalization$715.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.77
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTLA
Previous Symbol
CUSIPN/A
CIK1652130
Webhttp://www.intelliatx.com/
Phone857-285-6200

Debt

Debt-to-Equity Ratio0.05
Current Ratio7.89
Quick Ratio7.89

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.43 million
Price / Sales23.50
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.40 per share
Price / Book2.29

Profitability

EPS (Most Recent Fiscal Year)($1.98)
Net Income$-85,340,000.00
Net Margins-225.54%
Return on Equity-33.00%
Return on Assets-25.98%

Miscellaneous

Employees211
Outstanding Shares48,880,000
Market Cap$715.11 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:NTLA Rates by TradingView

(Ad)


In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics Inc (NASDAQ:NTLA) announced its quarterly earnings results on Thursday, October, 31st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.12. The business earned $10.60 million during the quarter, compared to the consensus estimate of $9.17 million. Intellia Therapeutics had a negative net margin of 225.54% and a negative return on equity of 33.00%. The business's revenue was up 43.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.53) EPS. View Intellia Therapeutics' Earnings History.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intellia Therapeutics.

What price target have analysts set for NTLA?

7 Wall Street analysts have issued 12 month price objectives for Intellia Therapeutics' stock. Their forecasts range from $16.00 to $57.50. On average, they expect Intellia Therapeutics' stock price to reach $26.92 in the next year. This suggests a possible upside of 84.0% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics.

What is the consensus analysts' recommendation for Intellia Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intellia Therapeutics.

What are Wall Street analysts saying about Intellia Therapeutics stock?

Here are some recent quotes from research analysts about Intellia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (1/15/2020)
  • 2. Chardan Capital analysts commented, "We see the Alnylam experience as particularly relevant given parallels between the 2 companies’ pipelines (transthyretin amyloidosis, primary hyperoxaluria) as well as the use of lipid-nanoparticle (LNP) technology to deliver CRISPR/Cas RNAs (Intellia) or siRNA therapeutics (Alnylam) to the liver. Dr Sepp-Lorenzino also has experience in delivery of nucleotide therapies outside the liver. Given Intellia’s prior work on delivery of LNPs to the central nervous system, to us, this appointment could signal further non-liver pipeline expansion in the longer term. Is the tide of CRISPR management departures turning? In our 22 January 2019 research, we noted the trend of executive turnover/ departures at the helm of CRISPR gene editing companies that occurred over the course of 2018/early-19." (5/28/2019)

Has Intellia Therapeutics been receiving favorable news coverage?

Media stories about NTLA stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Intellia Therapeutics.

Who are some of Intellia Therapeutics' key competitors?

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Canopy Growth (CGC), Netflix (NFLX) and QUALCOMM (QCOM).

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the folowing people:
  • Dr. John M. Leonard, Pres, CEO & Director (Age 62)
  • Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)
  • Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)
  • Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)
  • Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $14.63.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $715.11 million and generates $30.43 million in revenue each year. The company earns $-85,340,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.View Additional Information About Intellia Therapeutics.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is http://www.intelliatx.com/.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]


MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: 52-Week High/Low Prices For Stock Selection
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel